113 results
8-K
EX-99.1
IMCR
Immunocore Holdings plc
16 Sep 24
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
6:46am
statements. These statements include, but are not limited to, statements regarding expected clinical benefits of ImmTAC molecules, including KIMMTRAK … or licensing arrangements, including the risk that Immunocore may not realize the anticipated benefits of its collaboration with Bristol Myers Squibb
8-K
EX-99.1
IMCR
Immunocore Holdings plc
29 Aug 24
Immunocore announces transition of Chief Financial Officer
7:21am
, partnerships or licensing arrangements, including the risk that Immunocore may not realize the anticipated benefits of its collaboration with Bristol Myers
8-K
EX-99.1
IMCR
Immunocore Holdings plc
8 Aug 24
Immunocore reports second quarter financial results and provides a business update
7:21am
, but are not limited to, statements regarding the commercial performance of KIMMTRAK; the potential benefits and advantages that KIMMTRAK will provide for patients … clinical benefits and availability of the Company’s product candidates; and the use of the Company’s cash, cash equivalents and marketable securities. Any
8-K
EX-99.1
IMCR
Immunocore Holdings plc
31 May 24
Regulation FD Disclosure
4:21pm
regarding the expected clinical benefits of ImmTAC molecules, including KIMMTRAK, brenetafusp, and the Immunocore’s other product candidates, including … the benefits of the Company’s collaboration with Bristol-Meyers Squibb; and the timing and sufficiency of clinical trial outcomes to support potential
8-K
EX-99.1
omu0ui
30 May 24
Other Events
5:22pm
8-K
EX-10.2
ibn7fddb9fqmep
28 May 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-99.1
o0d9p6h
8 May 24
Immunocore reports first quarter financial results and provides a business update
7:13am
10-Q
rb659kisgzv a10sppuy
8 May 24
Quarterly report
7:00am
DEF 14A
afaxsy1dst
12 Apr 24
Definitive proxy
4:20pm
424B7
n5hk8eh6
5 Apr 24
Prospectus with selling stockholder info
4:34pm
PRE 14A
pc3mqe1e27r64n1u
2 Apr 24
Preliminary proxy
4:45pm
S-3ASR
79w17x
20 Mar 24
Automatic shelf registration
8:51pm
8-K
EX-99.1
d7uxq9mw5fi05ydxvlp
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
8-K
EX-99.2
xmc7hp
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
mzhb6klfpboki5pdce2u
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
uvwts3g3c9 a7hqu6kf
28 Feb 24
Annual report
7:33am
10-K
EX-97.1
ukas w6ysbf867b
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
kgtsvkr0mmzdb6bw4y
28 Feb 24
Annual report
7:33am
10-K
EX-10.12
rdkw75wubaq5
28 Feb 24
Annual report
7:33am